期刊文献+

造血干细胞移植术后患者环孢素A血药浓度动态分析及个体化用药指导

Personalized Medication of Cyclosporin A Guided by Concentration Monitoring after Haemopoietic Stem Cell Transplantation
下载PDF
导出
摘要 目的 1例再生障碍性贫血女性患者造血干细胞移植术后环孢素A的个体化给药剂量调整。方法持续的血药浓度监测,分析药物相互作用,调整口服给药剂量,使维持在合理治疗浓度范围。结果针对该例患者,环孢素A谷浓度控制在90~160 ng·ml-1范围内是安全有效的。结论通过药物代谢影响因素分析和制定环孢素A个体化给药方案,对于提高器官移植成功率,降低药物不良反应具有重要的临床意义。 Objective To regulate the personal dosage of cyclosporin A after haemopoietic stem cell transplantation due to aplastic anemia in a female patient.Methods Oral administration dosage was regulated by persistent monitoring of drug concentration and analyzing drug-drug interactions in order to obtain a rational therapeutic concentration range.Results The whole blood concentration of cyclosporin A that ranged from 90 to 160 ng·ml-1was clinically effective and safe in this patient.Conclusion Analysis and formulation of a personalized administration plan of cyclosporin A according to factors of drug metabolism can be very important for improving the success rate of organ transplantation and reducing adverse drug reactions.
出处 《解放军药学学报》 CAS 2014年第6期579-580,共2页 Pharmaceutical Journal of Chinese People's Liberation Army
关键词 治疗药物浓度监测 环孢素A 个体化给药 therapeutic drug monitoring cyclosporin A personalized medication
  • 引文网络
  • 相关文献

参考文献5

二级参考文献37

共引文献19

;
使用帮助 返回顶部